Publications

Pautus S, Alami M, Adam F, Bernadat G, Lawrence DA, De Carvalho A, Ferry G, Rupin A, Hamze A, Champy P, Bonneau N, Gloanec P, Peglion JL, Brion JD, Bianchini EP, Borgel D. Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1. Sci Rep. 2016 Nov 23;6:36462. doi: 10.1038/srep36462.

Carlson KS, Nguyen L, Schwartz K, Lawrence DA, Schwartz BS. Neuroserpin Differentiates Between Forms of Tissue Type Plasminogen Activator via pH Dependent Deacylation. Front Cell Neurosci. 2016 Jun 15;10:154. doi: 10.3389/fncel.2016.00154. eCollection 2016. PMID: 27378851.

Bondu V, Schrader R, Gawinowicz MA, McGuire P, Lawrence DA, Hjelle B, Buranda T. Elevated Cytokines, Thrombin and PAI-1 in Severe HCPS Patients Due to Sin Nombre Virus. Viruses. 2015 Feb 10;7(2):559-89. PMCID: PMC4353904

Wu J, Strawn TL, Luo M, Wang L, Li R, Ren M, Xia J, Zhang Z, Ma W, Luo T, Lawrence DA, Fay WP. Plasminogen Activator Inhibitor-1 Inhibits Angiogenic Signaling by Uncoupling Vascular Endothelial Growth Factor Receptor-2-aVb3 Integrin Cross Talk. Arterioscler Thromb Vasc boil. 2015 Jan;35(1):111-20. PMCID: PMC4270947.

Obi A, Diaz J, Ballard-Lipka N, Roelofs K, Farris D, Lawrence D, Henke P, Wakefield T. Low Molecular Weight Heparin Modulates Vein Wall Fibrotic Response in a PAI-1 Dependent Manner. J Vasc Surg Vanous Lymphat Disord 2014 Oct 1;2(4):441-450. PMCID: PMC4235166

Obi AT, Diaz JA, Ballard-Lipka NL, Roelofs KJ, Farris DM, Lawrence DA, Wakefield TW, Henke PK. PAI-1 over-expression decreases experimental post-thrombotic vein wall fibrosis by a non-vitronectin dependent mechanism. J Thromb Haemost. 2014 Jun 19; 12(8):1353-63. PMCID: PMC4127110

Zhong J, Yang HC, Kon V, Fogo AB, Lawrence DA, Ma J. Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts. Lab Invest. 2014;94:633-44. PMCID: PMC4361016

Zhang J, Gu C, Lawrence DA, Cheung AK, Huang Y. A PAI-1 mutant retards diabetic nephropathy in db/db mice through protecting podocytes. Exp Physiol 2014;99:802–15. PMCID: PMC4362754

Li SH; Reinke, AA; Sanders, KL; Emal, CD; Whisstock, JC; Stuckey, JA; Lawrence, DA. Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1. Proc Natl Acad Sci U S A. 2013 Dec 17;110(51);E4941-9. PMCID: PMC3870673

Osterholzer JJ, Christensen PJ, Lama V, Horowitz JC, Hattori N, Subbotina N, Cunningham A, Lin Y, Murdock BJ, Morey RE, Olszewski MA, Lawrence DA, Simon RH, Sisson TH. PAI-1 Promotes the Accumulation of Exudate Macrophages and Worsens Pulmonary Fibrosis Following Type II Alveolar Epithelial Cell Injury. J Pathol. 2012 Oct;228(2):170-80. PMCID: PMC3529409

Diaz JA, Ballard-Lipka NE, Farris DM, Hawley AE, Wrobleski SK,. Myers DD, Henke PK, Lawrence, DA, Wakefield, TW. Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis. J Vasc Surg. 2012 Mar;55(3):815-22. PMCID: PMC3289767

Courey, AJ, Horowitz, JC, Kim, KK, Koh, TJ, Subbotina, N, Warnock, M, Xue, B, Cunningham, AK, Lin, Y, Goldklang, MP, Simon, RH, Lawrence, DA, Sisson, TH. The vitronectin binding function of PAI-1 exacerbates lung fibrosis in mice. Blood 2011 Aug 25;118(8):2313-2321. PMCID: PMC3162358

Ji Y, Strawn TL, Grunz EA, Stevenson MJ, Lohman AW, Lawrence DA, Fay WP Multifaceted Role of Plasminogen Activator Inhibitor-1 in Regulating Early Remodeling of Vein Bypass Grafts. Arterioscler Thromb Vasc Biol. 2011 Aug;31(8):1781-1787. PMCID: PMC3141099

Garg N, Goyal N, Strawn TL, Wu J, Mann KM, Lawrence DA, Fay WP. Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices. J Thromb Haemost. 2010 Aug;8(8):1847-1854. PMCID: PMC2941703

Cale JM, Li SH, Warnock M, Su EJ, North PR, Sanders KL, Puscau MM, Emal CD, Lawrence DA. Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1 J Biol Chem 2010 Mar 12;285(11):7892-902. PMCID: PMC2832939

El-Ayache NC, Li SH, Warnock M, Lawrence DA, Emal CD. Novel bis-arylsulfonamides and aryl sulfonamides as inactivators of plasminogen activator inhibitor-1 (PAI-1). Bioorg Med Chem Lett. 2010 Feb 1;20(3):966-970. PMCID: PMC2957478

Huang Y, Border WA, Lawrence DA, Noble NA. Mechanisms underlying the anti-fibrotic properties of non-inhibitory PAI-1 (PAI-1R) in experimental nephritis. Am J Physiol Renal Physiol. 2009 Oct;297(4):F1045-F1054. PMCID: PMC2775568.

Wu J, Peng L, McMahon GA, Lawrence DA, Fay WP. Recombinant Plasminogen Activator Inhibitor-1 Inhibits Intimal Hyperplasia. Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1565-70. PMCID: PMC2771380

Fabre-Guillevin E, Malo M, Cartier-Michaud A, Peinado H, Moreno-Bueno G, Vallee B, Lawrence DA, Palacios J, Cano A, Barlovatz-Meimon G, Charriere-Bertrand C. PAI 1 and functional blockade of SNAI1 in breast cancer cells migration. Breast Cancer Res. 2008;10(6):R100 PMCID: PMC2656896.

Blake CM, Sullenger BA, Lawrence DA, Fortenberry YM. Antimetastatic potential of PAI-1-specific RNA aptamers. Oligonucleotides 2009 Jun;19(2):117-128. PMCID: PMC2948460

Li, SH, Gorlatova NV, Lawrence, D.A., & Schwartz, B.S. Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally-sensitive ligands. J. Biol Chem 2008 Jun 27;283(26):18147-57. PMCID: PMC2440609

Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol 2008 Feb;19(2):329–38. PMCID: PMC2396741

Maquerlot F, Galiacy S, Malo M, Guignabert C, Lawrence DA, d’Ortho MP, Barlovatz-Meimon G. Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing. Am J Pathol. 2006;169:1624-32

Liao H., Hyman, MC, Lawrence, DA, Pinsky DJ. Molecular Regulation of the PAI-1 Gene by Hypoxia: Contributions of Egr-1, HIF-1a , and C/EBPa. FASEB J. 2007 Mar;21(3):935-949.

Gorlatova NV, Cale JM, Elokdah H, Li D, Fan K, Warnock M, Crandall DL, Lawrence DA. Mechanism of inactivation of plasminogen activator inhibitor -1 by a small molecule inhibitor. J. Biol Chem 2007 Mar 23;282(12):9288-96.

Huang, Y., Border, W. A., Lawrence, D.A., Noble, N. A. Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. Kidney Int. 70:515-22, 2006.

Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence D.A. Effect of Pharmacologic PAI-1 Inhibition on Cell Motility and Tumor Angiogenesis. J Thromb Haemost. 4:2710-2715, 2006.

Crandall, D.L., Elokdah, H., Di, L., Hennan, J.K., Gorlatova, N.V., & Lawrence, D.A. Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in vivo efficacy. Journal of Thrombosis and Haemostasis, 2:1422-1428, 2004.

Stefansson, S., Yepes, M., Gorlatova, N., Day, D.E., Moore, E.G., Zabaleta, A., McMahon, G.A., & Lawrence, D.A. Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin G are more effective in vivo than their endogenous inhibitors. Journal of Biological Chemistry, 279:29981-29987, 2004.

Huang, Y., Haraguchi, M., Lawrence, D.A., Border, W.A., Yu, L., & Noble, N.A. A mutant, non-inhibitory plasminogen activator inhibitor-type 1 decreases matrix accumulation in experimental glomerulonephritis. Journal of Clinical Investigation, 112:379-388, 2003. (see commentaries Journal of Clinical Investigation, 112: 326-328. 2003; New England Journal of Medicine, 349: 2265-2266. 2003).

Gorlatova, N.V., Elokdah, H., Fan, K., Crandall, D.L., & Lawrence, D.A. Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis: Implications for serpin function. Journal of Biological Chemistry, 278: 16329-16335, 2003.

Stefansson, S., McMahon, G., Petitclerc, E., & Lawrence, D.A. Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling. Current Pharmaceutical Design, 9: 1545-1564. 2003.

<u>Reviews</u>

Li SH, Lawrence DA. Development of Inhibitors of Plasminogen Activator Inhbior-1. Methods in Enzymology. 501:177-207, 2011. PMID: 22078535

Cale, J.M., & Lawrence, D.A. Plasminogen Activator Inhibitor-1 as a Potential Therapeutic Agent. Curr Drug Targets. 8:971-981, 2007.

Yepes M., & Lawrence D.A. Neuroserpin in Neurological Disease; In: Molecular and Cellular Aspects of the Serpinopathies and Disorders in Serpin Activity: Gary A Silverman & David A Lomas (Eds.). World Scientific Publishing Co. Chapter 24, 2007.

Yepes, M., Loskutoff, D.J., & Lawrence, D.A. Plasminogen Activator Inhibitor-1. In: Hemostasis and Thrombosis : Basic Principles & Clinical Practice, Fifth Edition, Colman, R.W et al. (Eds.) Lippincott Williams & Wilkins, Chapter 19, 365-380; 2006.

Stefansson, S., & Lawrence, D.A.. Old dogs and new tricks, proteases, inhibitors and cell migration, Science STKE: 2003 Jul 1;2003(189):pe24. URL: http://stke.sciencemag.org/cgi/content/full/sigtrans;2003/189/pe24?ijkey=ZdV/2EIH2Ydt2&keytype=ref&siteid=sigtrans

Stefansson, S., Lawrence, D.A., Herren, T., & Plow, E.F. Novel Approaches to Thrombolysis Based on Modulation of Endogenous Fibrinolysis, In: Coron. Artery Dis., 9: 99-104. 1998.

Lawrence, D.A., & Loskutoff, D.J. Plasminogen Activator Inhibitor Type 1. In: Human Protein Data, 4th edition, Haeberli, A. (Ed.), Wiley-VCH, Weinheim, Germany. 1998.

Lawrence, D.A. The Role of Reactive-Center Loop Mobility in the Serpin Inhibitory Mechanism. In: Chemistry and Biology of SERPINS, F.C. Church, D.D. Cunningham, D. Ginsburg, M. Hoffman, S.R. Stone, and D.M. Tollefsen, (Eds.), Plenum Publishing, New York NY., Chapter 10, pp.99-108. 1997.

Lawrence, D.A. The serpin-proteinase complex revealed, News and Views, Nature Structural Biology, 4: 339-341. 1997.

Lawrence, D.A., & Ginsburg, D. Gene Expression and Function of Plasminogen Activator Inhibitor 1 (PAI-1). In: Fibrinolysis In Disease, Glas-Greenwalt, P., (Ed.), CRC Press Inc., Boca Raton FL., Chapter 3, pp 21-29. 1995.

Lawrence, D.A., & Ginsburg, D. Molecular Biology of Plasminogen Activator Inhibitors. In: Molecular Biology of Thrombosis and Hemostasis, Roberts, H.R., & High, K.A. (Eds.), Marcel Dekker Inc., New York, Chapter 25, pp 517-543. 1995.

Lawrence, D.A., Naski, M.C., Berkenpas, M.B., Palaniappan, S., Podor, T.J., Mosher, D.F., & Ginsburg D. The Interaction of Plasminogen Activator Inhibitor 1 with Vitronectin. In: Biology of Vitronectins and Their Receptors, Preissner, K.T., Rosenblatt. S., Kost, C., Wegerhoff, J., & Mosher, D.F. (Eds.), Elsevier Science Publishers B.V., Amsterdam, The Netherlands, pp. 303 310. 1993.

Ny, T., Lawrence, D.A., Mikus, P., Strandberg, L., & Åstedt, B. Structure-Function Analysis of Plasminogen Activator Inhibitors Type 1 and 2 Using In Vitro Mutagenesis. In: Protease Inhibitors, Takada, A., Samama, M.M., and Collen, D. (Eds.), Elsevier Science Publishers B.V., Amsterdam, The Netherlands, pp 23-36. 1990.

Loskutoff, D.J., Ny, T., Sawdy, M., & Lawrence, D.A. The Fibrinolytic System of Cultured Endothelial Cells: Regulation by Plasminogen Activator Inhibitor. In: Proteases in Biological Control and Biotechnolog y: proceedings of a Lilly-UCLA Symposium held in Park City, Utah, February 9-16, 1986, Cunningham, D. and Long, G. (Eds.), Alan R. Liss, Inc., pp 101 108. 1987.